

EFFECTIVE March 4, 2015

Re: Notification of Changes to Test Result Reports

We would like to make you aware of the following changes to test reports, effective 3/4/2015. The changes outlined below do not affect fields that contain patient information or patient test results.

Format Changes:

- The test methodology has been added to each test report
- A required HIPAA privacy statement has been moved to above the footer at the bottom of the test report
- Format of MiraVista Diagnostics logo has changed to a vertical format and the address and phone number have been justified to the right within header


Content Changes:

- In accordance with new CAP requirements, a statement related to laboratory developed tests, has been added to MVista[®] Histoplasma Antigen, MVista[®] Blastomyces Antigen, MVista[®] Coccidioides Antigen, and Itraconazole Level reports
- MVista[®] Coccidioides Antigen reportable range has been changed to 0.07 – 8.2 ng/mL in the interpretive guidelines
- MVista[®] Coccidioides Antigen reportable range of “Positive, Below the Limit of Quantification” has been removed from the interpretive guidelines
- Reference interval of “Negative, No Antibody Detected” has been added to all antibody by immunodiffusion reports
- Fungitell™ assay reportable range has been revised to from 31 - 500 pg/mL, to <31 - >500 pg/mL, to more accurately represent validated reportable range.

Fields containing patient information and results are not changing. The noted changes are being made to static fields, in order to remain compliant with regulatory requirements and to correct minor clerical and formatting issues. Please contact MiraVista Diagnostics at 866-647-2847 with any questions.

Thank you for your business. MiraVista Diagnostics values your continued support.

Sincerely,



L. Joseph Wheat, MD
Medical Director